Clinical Management of Episodic Memory Changes in Dementia

Current Treatment Options in Neurology
Po-Heng Tsai

Abstract

The purpose of this review was to discuss therapeutic options available for the treatment of memory difficulties in dementia. Because of the lack of progress in the availability of new medications, there has been an increased interest in focusing on non-pharmacological means to management cognitive symptoms related to dementia. The clinical management of memory loss should focus both on pharmacological and non-pharmacological approaches. Treatment with medications should usually begin with a cholinesterase inhibitor and then followed by addition of memantine if there is a decline. In addition to medication management, emphasis should be placed on the importance of maintaining a healthy lifestyle that encompasses physical activities, cognitive stimulation, and a healthy diet.

References

Jul 2, 2003·Journal of the American Geriatrics Society·David S GeldmacherJohn R Ieni
Dec 23, 2003·Current Medical Research and Opinion·Serge GauthierSteven G Potkin
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Pierre N TariotUNKNOWN Memantine Study Group
Jun 3, 2004·Annals of Neurology·Marsel MesulamSandra Weintraub
Feb 18, 2005·The New England Journal of Medicine·Andrew E Budson, Bruce H Price
Nov 26, 2005·Current Medical Research and Opinion·Yu Ko, Stephen Joel Coons
Nov 26, 2005·Current Medical Research and Opinion·L BartorelliUNKNOWN Upgrade Study Group
Apr 21, 2006·The Cochrane Database of Systematic Reviews·R McShaneN Minakaran
Oct 13, 2006·Archives of Neurology·Nikolaos ScarmeasJose A Luchsinger
Nov 30, 2006·Alzheimer Disease and Associated Disorders·Howard H FeldmanUNKNOWN Memantine MEM-MD-02 Study Group
Dec 7, 2007·The Annals of Pharmacotherapy·Ian D MaidmentCornelius L Katona
Nov 6, 2008·International Journal of Geriatric Psychiatry·Howard H FeldmanShane Kavanagh
Jul 10, 2009·The Cochrane Database of Systematic Reviews·Fábio GuidugliAlvaro N Atallah
Aug 19, 2010·Nature Reviews. Neurology·Verena BuschertHarald Hampel
Mar 19, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN Alzheimer's Association
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Bob WoodsMartin Orrell
Apr 17, 2012·Exercise and Sport Sciences Reviews·Margie H DavenportMarc J Poulin
Oct 23, 2012·Archives of Medical Research·Kirk I EricksonOscar L Lopez
Jan 22, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Carolyn W ZhuYaakov Stern
Jun 7, 2013·The Cochrane Database of Systematic Reviews·Alex Bahar-FuchsBob Woods
Aug 22, 2013·International Psychogeriatrics·Nicolas FarinaNaji Tabet
Dec 3, 2014·The American Journal of Medicine·R Jay WidmerAmir Lerman
Apr 16, 2015·The Cochrane Database of Systematic Reviews·Dorothy ForbesSean Forbes
Oct 23, 2015·Neurology·Yian GuNikolaos Scarmeas
Mar 12, 2016·Journal of Alzheimer's Disease : JAD·Cyrus A RajiLewis H Kuller
Jul 20, 2016·BMC Geriatrics·Andreas LauenrothBirgit Teichmann
Sep 17, 2016·Advances in Nutrition·Sara Danuta Petersson, Elena Philippou
May 21, 2017·Journal of Alzheimer's Disease : JAD·Ryan J DoughertyOzioma C Okonkwo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.